BRCA1 and neoplasm: The authorsrevealed that patients with cancers exhibiting BRCA1-immunostaining in less than 10%of the tumor cells was the only subgroup exhibiting a significant benefit in OS froma platinum-based IP chemotherapy.22 In addition, Carser et al. found also a strongresponse improvement to classical i.v. platinum-based chemotherapy in tumors withabsent or low BRCA1-expression in immunohistochemistry.